Professor Karl Peggs
Karl Peggs is a Professor of Transplant Science and Cancer Immunotherapy, Scientific Director NIHR Blood and Transplant Research Unit for Stem Cells and Immunotherapies, Scientific Co-Chair and Board Member of the British Society of Blood and Marrow Transplantation, and Honorary Consultant in Haematology/Stem Cell Transplantation at UCLH; he is also an Honorary Consultant (non-clinical) at the Royal Marsden Hospital, London. After taking the position of Senior Lecturer at UCL in 2003 and Head of Adult Stem Cell Transplantation Services, UCLH, he spent over 2 years at MSKCC, NYC, USA in the laboratory of Professor James Allison studying murine models of regulatory checkpoint blockade. He runs a joint Research Laboratory with Dr Sergio Quezada in the UCL Cancer Institute and his research interests include viral infections, immune reconstitution, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics. More recently he has established the clinical translational side of the academic CAR T cell programme at UCLH.
Karl was trained at the John Radcliffe Hospital, Oxford, Addenbrooke’s Hospital, Cambridge, and UCH, London.
Professor Charles Swanton
Charlie Swanton is a Royal Society Napier Professor of Cancer and consultant thoracic oncologist at UCL Hospitals and group Leader of the Translational Cancer Therapeutics laboratory at Cancer Research UK (CRUK) and the Francis Crick Institute. He is a world leader in the understanding of genomic diversity within cancers (intratumour heterogeneity) and molecular mechanisms driving cancer branched evolution. He has published over 130 papers and is the recipient of a number of awards in recognition of his research. He is the co-director of the CRUK Lung Cancer Centre of Excellence and an appointed Fellow of the European Academy of Cancer Sciences (2014) and a Fellow of the Academy of Medical Sciences (2015). He is chief investigator of the UK cancer evolution program TRACERx. He has unparalleled experience in cell biology, bio-informatics and the development of a sequencing pipeline for the prediction and annotation of neo-antigens.
Charlie holds an MB BS and first class honors degree in Cell Biology and Immunology from UCL medical schools and Ph.D. from the Imperial Cancer Research Fund.
Chris is Chief Executive Officer and a Partner of Syncona Partners LLP. He is a seasoned biotech entrepreneur with over 30 years’ experience in the industry. From 2004 he served at the Chief Executive Officer of Argenta Discovery Ltd. (acquired by Galapagos NV in 2010) and later Pulmagen Therapeutics Limited. During this time, he successfully transitioned the company from early stage drug discovery to a mid-stage clinical development organisation. Chris has considerable expertise in leading and growing early stage companies and extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).
Martin is the Chief Executive Officer of Syncona Partners LLP. Previously, he was a Partner at MVM Life Science Partners LLP, a leading venture capital company focused on life science and healthcare investments. During his time at MVM, Martin was a member of the Management and Investment Committees and led MVM’s European operations. He was involved in a number of successful investments including PregLem SA (sold to Gedeon Richter), Momenta Pharmaceuticals, Inc, (NASDAQ: MNTA), Healthcare Brands International (sold to Meda AB) and Heptares Therapeutics Ltd. Before MVM, Martin had roles with 3i Group plc and McKinsey & Company. Martin has a PhD in Biochemistry from Cambridge University.